Elevation Oncology Terminates EO-3021 Study Amid Implications for Future Research and Development Strategies
ByAinvest
Friday, Jul 4, 2025 12:04 am ET1min read
ELEV--
LLY--
Elevation Oncology's Phase 1 study on EO-3021, an anti-claudin 18.2 antibody drug conjugate, has been terminated. The study aimed to evaluate EO-3021's safety and efficacy in treating solid tumors expressing CLDN18.2. The termination could impact Elevation Oncology and its partners, Eli Lilly, GlaxoSmithKline, and CSPC Pharmaceutical Group. Further details can be accessed on the ClinicalTrials portal.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet